Medtronic commences U.S. and international launch of its Amphirion Plus PTA catheter and closes enrollment in a study of its IN.PACT Amphirion drug-eluting balloon.

Medical device giant Medtronic (NYSE:MDT) made progress in a pair of below-the-knee vascular devices, announcing U.S. and international launch of the Amphirion Plus PTA catheter and closing enrollment in a clinical trail of its IN.PACT Amphirion drug-eluting balloons.

Both devices treat periphery artery disease, with the Amphirion Plus PTA indicated for treatment of narrowed or blocked leg arteries below the knee and the IN.PACT Amphirion drug-eluting balloon used to treat critical limb ischemia, a more serious form of PAD, according to a Medtronic press release.